PORTLAND — Attorney General Janet T. Mills says the MaineCare program will be reimbursed more than $74,000 under a settlement between Allergan Inc. and the federal government and states over how the company markets Botox.
Allergan agreed to pay $600 million to settle a federal investigation into the marketing of its wrinkle-smoothing drug Botox. The U.S. Justice Department says Allergan acknowledged marketing Botox to physicians for unapproved uses including headaches, spasticity, crossed eyes and underarm sweating.
The investigation was sparked by a whistleblower complaint.
California-based Allergan also reached an agreement with the Department of Health and Human Services’ Office of the Inspector General that requires the company to submit compliance reports.
Send questions/comments to the editors.
Success. Please wait for the page to reload. If the page does not reload within 5 seconds, please refresh the page.
Enter your email and password to access comments.
Hi, to comment on stories you must . This profile is in addition to your subscription and website login.
Already have a commenting profile? .
Invalid username/password.
Please check your email to confirm and complete your registration.
Only subscribers are eligible to post comments. Please subscribe or login first for digital access. Here’s why.
Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.